The NCCN Kidney Cancer Clinical Practice Guidelines in OncologyTM

Overview In 2008, an estimated 54,390 Americans were diagnosed with kidney cancer and 13,010 died of the disease in the United States.1 Renal cell carcinoma (RCC) comprises approximately 2% of all malignancies, with a median age at diagnosis of 65 years. The rate of RCC has increased 2% per year for the past 65 years. The reason for this increase is unknown. Approximately 90% of renal tumors are RCC, and 85% of these are clear cell tumors.2 Other, less-common cell types include papillary, chromophobe, and Bellini (collecting) duct tumors. Collecting duct carcinoma comprises fewer than 1% of all cases. Medullary renal carcinoma is a variant of collecting duct renal carcinoma and was initially described as occurring in patients who are sickle cell–trait positive. Smoking and obesity are among the risk facThe NCCN

[1]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[2]  R. Figlin,et al.  Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) , 2008 .

[3]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[4]  J. Elting,et al.  Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis , 2007 .

[5]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[6]  L. Chow,et al.  Sunitinib: from rational design to clinical efficacy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Bukowski,et al.  Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Staehler Sorafenib in Advanced Renal Cancer , 2007, Drugs.

[9]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[10]  P. Russo Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma , 2006 .

[11]  David C. Miller,et al.  Surgical management of low-stage renal cell carcinoma: Technology does not supersede biology. , 2006, Urology.

[12]  O. Rouvière,et al.  Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up? , 2006, Nature Clinical Practice Oncology.

[13]  A. Oza,et al.  Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Jeffrey W. Clark,et al.  Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors , 2005, Clinical Cancer Research.

[15]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[16]  M. Piccart,et al.  Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours , 2005, British Journal of Cancer.

[17]  F. Marshall Phase II Clinical Trial of Interactive MR Imaging-Guided Interstitial Radiofrequency Thermal Ablation of Primary Kidney Tumors: Initial Experience , 2005 .

[18]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Milowsky,et al.  Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma , 2004, Cancer.

[20]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[21]  D. Gervais,et al.  Radiofrequency ablation: an alternative treatment method of renal cell carcinoma. , 2004, Chang Gung medical journal.

[22]  E. Small,et al.  A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Cheville,et al.  Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. , 2004, The Journal of urology.

[24]  R. Figlin,et al.  Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Steinberg,et al.  Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[27]  J. Manola,et al.  Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  V. Sukhatme,et al.  Renal cancer: molecular mechanisms and newer therapeutic options , 2002, Current opinion in nephrology and hypertension.

[29]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[30]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[31]  J. Buer,et al.  Capecitabine in the treatment of metastatic renal cell carcinoma , 2000, British Journal of Cancer.

[32]  M. Burt,et al.  Resection of metastatic renal cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[34]  R. Fisher,et al.  Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. , 1997, The cancer journal from Scientific American.

[35]  H. Hricak,et al.  Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. , 1985, Radiology.

[36]  W. Gunn Cancer: Principles and Practice of Oncology , 1982 .

[37]  S. Fosså,et al.  Radiotherapy of metastases from renal cancer. , 1982, European urology.

[38]  M. Gordon Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 , 2009 .

[39]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[40]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Lam,et al.  Open partial nephrectomy for the treatment of renal cell carcinoma , 2006, Current urology reports.

[42]  B. Konety Renal cryoablation: Outcome at 3 years , 2006 .

[43]  M. Blute,et al.  Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. , 2003, The Journal of urology.

[44]  P. Choyke,et al.  Hereditary renal cancers. , 2003, Radiology.

[45]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  G. Kramer,et al.  Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  D. Mendelson,et al.  Comparison of MRI and CT for study of renal and perirenal masses. , 1991, Critical reviews in diagnostic imaging.